These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17942884)

  • 21. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 22. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
    Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
    Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 24. Trastuzumab beyond disease progression: case closed?
    Valabrega G; Aglietta M; Montemurro F
    J Clin Oncol; 2009 Sep; 27(27):e121-2; author reply e124-5. PubMed ID: 19687323
    [No Abstract]   [Full Text] [Related]  

  • 25. Resistance to trastuzumab: a necessary evil or a temporary challenge?
    Cardoso F; Piccart MJ; Durbecq V; Di Leo A
    Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab resistance: role for Notch signaling.
    Mehta K; Osipo C
    ScientificWorldJournal; 2009 Dec; 9():1438-48. PubMed ID: 20024517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab: designer drug or fashionable fad?
    Freebairn AJ; Last AJ; Illidg TM
    Clin Oncol (R Coll Radiol); 2001; 13(6):427-33. PubMed ID: 11824879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translational cancer research in Europe.
    Fricker J
    Mol Oncol; 2007 Jun; 1(1):8-10. PubMed ID: 19399957
    [No Abstract]   [Full Text] [Related]  

  • 29. Human epidermal growth factor receptor 2 testing recommendation.
    Raji A; Lurie RH
    Arch Pathol Lab Med; 2007 Sep; 131(9):1330-1; author reply 1331-3. PubMed ID: 17824785
    [No Abstract]   [Full Text] [Related]  

  • 30. Trastuzumab--mechanism of action and use.
    Mir O; Berveiller P; Pons G
    N Engl J Med; 2007 Oct; 357(16):1664-5; author reply 1665-6. PubMed ID: 17948347
    [No Abstract]   [Full Text] [Related]  

  • 31. Breast cancer biology blossoms in the clinic.
    Nass SJ; Hahm HA; Davidson NE
    Nat Med; 1998 Jul; 4(7):761-2. PubMed ID: 9662357
    [No Abstract]   [Full Text] [Related]  

  • 32. Trastuzumab: possible publication bias.
    Metcalfe S; Burgess C; Laking G; Evans J; Wells S; Crausaz S
    Lancet; 2008 May; 371(9625):1646-8. PubMed ID: 18486728
    [No Abstract]   [Full Text] [Related]  

  • 33. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy.
    Fox KF
    Br J Cancer; 2006 Nov; 95(10):1454. PubMed ID: 17060943
    [No Abstract]   [Full Text] [Related]  

  • 35. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 targeted therapy in breast cancer...beyond Herceptin.
    Pal SK; Pegram M
    Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
    Araki K; Pegram M
    Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800
    [No Abstract]   [Full Text] [Related]  

  • 38. Cerebral metastases in patients with advanced breast cancer treated with trastuzumab.
    Atkinson J; Peace J; Crawford SM
    Am J Clin Oncol; 2004 Apr; 27(2):212. PubMed ID: 15057165
    [No Abstract]   [Full Text] [Related]  

  • 39. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
    Heinzl S
    Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
    [No Abstract]   [Full Text] [Related]  

  • 40. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
    Tanvetyanon T
    JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.